Idorsia's goal is to discover, develop and bring more, innovative medicines to patients. We believe that delivering on this mission is our core responsibility to our stakeholders and society in general. We also believe that it is possible to achieve this in an economically, socially and environmentally responsible manner.

Idorsia’s stakeholders value excellence in governance. We aim to be transparent, applying the highest standards of integrity across the company.

Our Legal & Compliance function seeks to drive a culture of integrity, with the following priorities:

  • communicate clearly to employees
  • focus on key compliance risk areas
  • improve compliance behavior through training and support
  • ensure that employees can raise concerns and that these are properly addressed
  • ensure fair and objective investigations of potential policy breaches

An example of best practice in governance is our Code of Business Conduct, which underpins our commitment to integrity and sets out fundamental rules for interacting with others as we drive our business forward. Supporting policies, standard operating procedures and guidelines provide more detail on how our high-level commitments are to be applied in practice.

All Idorsia employees have undergone mandatory training to ensure compliance with the Code.

The Idorsia Code of Business Conduct is at the foundation of our corporate culture and defines the core principles and ethical standards by which we create value in our company. It is the responsibility of every Idorsia employee to be familiar with and to comply with our Code.

We are proactive in establishing policies and practices that support strong corporate governance and transparency. These policies and practices are continually reviewed and enhanced as appropriate.

Privacy & Data Security

Idorsia understands the importance of protecting personal information and applying the highest ethical and regulatory standards. We are committed to respecting our stakeholders’ privacy and safeguarding their personal information. Idorsia’s data protection policy covers all personal data on study participants, healthcare professionals, customers, suppliers and employees. 

To ensure the integrity and privacy of personal and health-related information provided to us, we use state-of-the-art information security programs, focusing on protection of sensitive information and detection of unauthorized access. 

Corruption & Bribery

Full compliance with applicable laws in all the regions where Idorsia operates is crucial to our success. Idorsia’s position is clearly stated in its Anti-Corruption and Anti-Bribery Policy: We take a zero-tolerance approach to bribery and corruption and are committed to acting professionally in all our business dealings and relationships wherever we operate.

We implement and enforce effective systems to counter bribery. We will uphold all laws relevant to countering bribery and corruption in all the jurisdictions in which we operate. All Idorsia employees are required to undergo training on this policy.

Labor & Human Rights

Idorsia respects the rights of its employees as set out in the Universal Declaration of Human Rights, and we fully comply with all relevant laws, rules and regulations governing labor, employment and the employment relationship in all the countries where we operate.

We respect the right of all employees to join a legally recognized employee association, and we comply with all laws relating to employee representation. We strive to maintain an open dialogue with all our employees and their representatives. 

Due to the nature of our business and the location of our operations, the risk of child or forced labor is minimal. We do, however, remain vigilant for unexpected issues that may arise – not only in our own operations but also in relation to our procurement practices. Our expectations regarding working conditions, human rights protection, business ethics, legal compliance and environmental protection are set out in our Code of Conduct.

Research ethics

We strive to maintain the highest ethical, scientific and clinical standards in all our research activities, and to comply with all national and international standards. Idorsia regularly reviews its research policies to align them with its strategic objectives and with the evolving values and goals of stakeholders.

Regulatory authorities around the world require pharmaceutical companies to test all new drugs before they are launched, and there is no alternative to including some animal testing as part of this process. This is essential both for scientific reasons and to safeguard the volunteers and patients who take part in subsequent clinical trials. As a fundamental principle, we support the “three R’s” in relation to animal testing:

Refinement – Alleviate or minimize impacts to animals by reducing potentially painful or invasive procedures, whenever possible.

Reduction – Use the absolute minimum number of animals required to obtain valid results in each study.

Replacement – Always look for alternative, non-animal-based research methods where possible.

The number of animals used in drug development has dropped dramatically over the past three decades as a result of industry initiatives like this. Idorsia has a strong policy on the care, welfare and treatment of animals, and we conduct regular audits to make sure that our expectations are being met, whether the studies are being conducted in-house or outsourced.

In addition, we ensure that the use and care of all laboratory animals meets or exceeds relevant local, national and international regulations. Our programs and facilities are subject to unannounced regulatory review and inspections. For sponsored work at contract research organizations, our animal welfare oversight activities include regular on-site evaluations by our veterinary staff.

Idorsia will never use great apes (gorillas, chimpanzees, orangutans and bonobos) in its research.

Clinical Trials Transparency

Clinical trials are essential to the development of innovative medicines. We are committed to the highest standards of quality and ethical conduct in all our clinical research. Our trials are performed in accordance with internationally accepted guidelines, and protocols are evaluated by independent review boards and ethics committees prior to study initiation. We are also dedicated to improving public health through responsible clinical trial 
data transparency which – while complying with applicable regulations – respects our proprietary information and patients’ privacy.

Materiality Analysis

Although we are a young company, we have already – thanks to our teams’ experience of working together – established a robust governance framework, with a broad range of supporting policies, standard operating procedures, and guidelines (such as our Code of Business Conduct), driving a culture of integrity.

As we look forward to a strong growth trajectory, it is important that we are open and transparent about how we run our business, and about other topics that matter to our stakeholders. We are therefore conducting a materiality analysis and associated stakeholder engagement activities to lay the foundations for future sustainability reporting, also known as non-financial or environmental, social & governance (ESG) reporting.

In 2019, based on an analysis of ESG reports from a group of Idorsia’s peers, we prepared a list of material sustainability topics and drew up a map of key stakeholders. This forms the basis for stakeholder engagement activities to be pursued in 2020, with a view to producing a materiality matrix.

These activities will allow us to develop an appropriate sustainability reporting strategy and to identify areas for improvement, as well as specific actions and initiatives.